CD19 and non-Hodgkin lymphoma: In July 2020, Shalabi et al. reported a second retrospective study of the effects of CD19 CAR T-cell therapy on cardiac function in 52 pediatric and young adult patients with relapsed/refractory B-ALL or non-Hodgkin lymphoma.